Why the Pediatric Medtech Innovation Needs a Different Playbook with Cory Criss
- 19 hours ago
- 4 min read
Pediatric Medtech Innovation
Pediatric medtech does not suffer from a lack of good ideas as much as it suffers from a lack of coordinated infrastructure to move those ideas forward.
Pediatric innovation is often framed as a design challenge: build smaller, safer, more specialized devices for children. But the deeper challenge is structural. Pediatric patients have distinct clinical needs, yet the market dynamics, funding pathways, evidence requirements, and hospital access points are dramatically different from adult medtech.
Children are not simply smaller adults, and pediatric device development is not simply adult device development at a smaller scale. The path requires specialized design thinking, stronger clinical collaboration, more creative funding models, and infrastructure that can help promising ideas move through a more complex commercialization environment.
Pediatric devices are not scaled-down adult devices
One of the biggest misconceptions in pediatric medtech is that adult technologies can simply be resized for children. In reality, children are not one uniform patient population. Neonates, infants, young children, and teenagers can have vastly different anatomical, physiological, and clinical needs.
As Dr. Cory Criss put it: “Sizes change. Kids grow. You can’t just make one size fits all.”
That creates complexity across device design, testing, clinical use, and adoption. A catheter, implant, surgical tool, or software as a medical device may need to account for growth, body size, developmental stage, long-term safety, and future procedures in ways adult technologies often do not.
The design challenge is real, but it is only one part of the problem. Pediatric medtech also has to account for smaller patient populations, fewer specialized centers, and a more difficult path to generating evidence.
Pediatric medtech has a scale problem
Pediatric companies face a difficult market reality. There are far fewer children’s hospitals than adult hospitals, which affects clinical evidence generation, commercialization, site access, purchasing pathways, investor appetite, and adoption.
Dr. Criss noted that there are roughly 40 to 50 freestanding children’s hospitals compared with thousands of adult hospitals. That difference makes multi-institutional collaboration essential. A single hospital may not be enough to prove the value of a technology, especially when the target population is small, specialized, or clinically complex.
The challenge is not that the need is small. The challenge is that the pathway to serving that need is harder to organize.
That distinction matters. Pediatric patients represent a meaningful portion of the population, but the commercial pathways do not always reflect the scale or urgency of the need. Companies may face longer evidence timelines, more fragmented access, and a smaller perceived market, even when the clinical impact could be significant.
The issue isn't ideas. It is execution pathways
Pediatric innovation is not stalled because clinicians, founders, or engineers lack ideas. Many health systems have clinicians with firsthand knowledge of unmet needs. Many startups have promising technologies. Many engineers can imagine better tools.
The harder question is how those ideas move forward.
“The challenge was actually having a structured mechanism that finds those opportunities, supports them, executes on them within the hospital system,” Dr. Criss said.
Without a mechanism to evaluate, de-risk, fund, test, and connect ideas to the right stakeholders, pediatric innovation can stall long before it reaches patients. A good idea still needs regulatory guidance, clinical input, institutional access, evidence generation, funding, and a realistic path to adoption.
This is where structures like the Midwest Pediatric Device Consortium, or MPDC, become important. The goal is not only to provide funding, but to create a pathway for pediatric device companies to access expertise, advisors, regulatory support, clinicians, and hospital environments.
Hospital access can become a strategic advantage
For pediatric medtech companies, hospital access is often one of the hardest milestones to achieve. Once secured, it can become one of the strongest indicators of credibility.
“You have to get buy-in from a hospital somewhere with clinician buy-in,” Dr. Criss said.
That does not only mean finding one enthusiastic physician. It means understanding purchasing, value analysis, clinical trials, evidence generation, workflow, and how a hospital might actually adopt the technology.
For companies entering the U.S. market, this is especially important. A strong technology alone is rarely enough. Companies need proof that clinicians see value, hospitals can engage, and the product can fit into the realities of care delivery.
Why this matters
Pediatric patients deserve technologies designed for their realities, not adapted as an afterthought. But the traditional medtech playbook does not always work well for pediatric innovation. Smaller markets, limited funding, specialized clinical environments, and more complex evidence needs all make the path harder.
The answer is not simply telling more founders to build pediatric devices. The answer is building systems that make pediatric innovation more viable.
That includes non-dilutive funding, clinician access, regulatory guidance, multi-site collaboration, hospital engagement, and better pathways from unmet need to market-ready solution.
What to watch
The key question is whether pediatric medtech infrastructure can become sustainable beyond grant cycles.
If consortia, innovation centers, hospital networks, investors, and industry partners can align around repeatable models, pediatric device development could become less fragmented and more investable. That would not eliminate the complexity of the space, but it could make the path more navigable for serious innovators.
The practical implication for startups is clear: build hospital engagement early. Understand the evidence burden. Find clinician champions, but do not stop there. Learn how value analysis, purchasing, workflow, and clinical validation will shape adoption.
Pediatric medtech needs big ideas; but, the ideas are only the beginning.
To learn more, listen to the full Project Medtech Podcast episode with Cory Criss:
Comments